-
ASCO GU 2021: PSA drop depth is closely related to survival results in patients treated with Nzarumide (PROSPER trial)
Time of Update: 2021-02-24
In this post-mortem analysis, the authors divided the patients into four groups based on the level of PSA decline at the lowest point: slt;50% (reference value), 50-90%, 90% or higher (lowest point≥0.2 ng / mL, 90% or higher, lowest point , 0.2 ng / mL.
-
Several key studies that must be read in the field of prostate cancer in 2020
Time of Update: 2021-02-24
a total of 2,103 men with MRI visible prostate lesions received MRI targeted and systematic biopsies, the main results of which were cancer, according to the hierarchy.
the authors found that 1,312 (62.4%) of cancers were diagnosed in combination, while 404 men (19.2%) received treatment for prostate cancer.
-
Lancet oncol: BRAFv600 mutant ctDNA can be used as an independent predictive biomarker for melanoma targeting treatment prognosis
Time of Update: 2021-02-24
in comBI-d trials, ctDNA was not detected at 4 weeks to be significantly associated with progression-free survival and total lifetime extension, especially in patients with elevated lactic acid dehydrogenase (HR 1.99, 95% CI 1.08-3.64, p=0.027; 2.38, 1.24-4.54, p=0.0089）。 , the detection of BRAFv600 mutation ctDNA before and after treatment can be used as an independent predictive biomarker for clinical prognosis of melanoma-targeted treatment.
-
Eur Radiol: What are the advantages and disadvantages of APT and DKI in diagnosing breast cancer?
Time of Update: 2021-02-24
Recently, a study published in the Journal of European Radiology compared the effects of DKI and APTWI in identifying breast health and malignant lesions, and analyzed the correlation between derivative parameters and breast cancer prognosis factors, providing new ideas for breast cancer diagnosis, treatment and prognosis.
-
Navuliyu monoantigen is used to treat the successful treatment of muscle layer immersion urethra cancer after rooting surgery (CheckMate -274 study)
Time of Update: 2021-02-24
CheckMate-274 is a randomized, double-blind, multi-center Phase 3 clinical study designed to assess the efficacy and safety of Odivo (Navuliyu monoanti) compared placebo for patients with high risk of recurrence of muscle-layer immersive urethroid cancer after surgery.
-
Br J Cancer: Breast Cancer Prognosm analysis after new complementary chemotherapy: Comparison of RCB and Neo-Bioscore scores
Time of Update: 2021-02-24
results showed that RCB and Neo-Bioscore scores were significantly associated with disease-free and overall survival rates in the global population and in patients with triple negative BC.
-
Fda approves Cosela (trilaciclib) to reduce bone marrow inhibition caused by chemotherapy
Time of Update: 2021-02-24
Recently, the U.S. Food and Drug Administration (FDA) approved Cosela (trilaciclib) to reduce the rate of bone marrow inhibition caused by chemotherapy in patients with small cell lung cancer.
phase III randomized, double-blind, placebo-controlled study evaluated the efficacy of Trilaciclib in patients with broad-stage small cell lung cancer.
-
Gut: Professor Li's team has discovered new mechanisms for pancreatic cancer metastasis and proposed new strategies for targeted treatment
Time of Update: 2021-02-24
Recently, Li Wei, chief professor of Shanghai University of Traditional Chinese Medicine, published an article online in the international landmark journal GUT, "Eingy cell-derived CXCL3 promotes panc
-
Eur J Cancer: Intensive radiotherapy activates phase I dose incremental studies of NBTXR3 in elderly patients with local late-stage head and neck squamous cell carcinoma
Time of Update: 2021-02-23
Phase I study evaluated the safety of the state-of-the-art radiation enhancer nanoparticle NBTXR3 in elderly or weak patients with local late-stage head and neck squamous cell carcinoma who were not suitable for chemotherapy.
-
Plos Med: Maintaining a healthy lifestyle can greatly reduce the risk of colorectal cancer
Time of Update: 2021-02-23
The proportion of CRC cases that may be prevented by endoscopic screening alone (PAR) was 32% (95% CI, 31% to 33%), and when combined with a healthy lifestyle (score s 5), increased to 61% (95% CI, 42% to 75%).
-
The UK MHRA allows clinical trials of amycin "pre-drug" AVA6000 to treat solid tumors
Time of Update: 2021-02-23
Pharmaceutical company Avcta recently announced that it has been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to begin a Phase I clinical trial of AVA6000, a "pre-drug" of amycin.
-
NEJM: New Hope for Lymphoma Patients! CAR-T is still in remission after 5 years of treatment
Time of Update: 2021-02-23
the researchers treated Kymriah after receiving standard treatment in 24 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of NHL, but the cancer returned.
-
Nat Med: Clinical studies of patients with non-small cell lung cancer who can undergo surgery with the new auxiliary drug Narvon anti-monodrive therapy or combined Ipi monotherapy
Time of Update: 2021-02-23
Pathological and radiotherapy responses in two treatment groups in the study, the researchers reported 44 surgically performable NSCLC patients and conducted phase 2 randomized NEOSTAR clinical trials (NCT03158129) of the new complementary drug Narvon anti-monodrive therapy or navudosant anti-monotherapy with the primary pathological response (MPR) as the primary endpoint.
-
Eur Radiol: Calcification of Mammary Targets - What is the clinical significance of suspected morphological calcification?
Time of Update: 2021-02-23
A recent study published in the journal European Radiology included distribution and clinical factors in two separate female cohorts, evaluating PPV with suspicious forms of calcification and providing more practical guidance for the treatment of suspected calcification stoves detected in mammary targets.
-
How to treat metastasis grape membrane melanoma? FDA awards tebentafusp 'breakthrough therapy title'
Time of Update: 2021-02-23
Immunocore, a late-stage biotechnology company dedicated to developing new T-cell-specific (TCR) dual-specific immunotherapy, announced today that the U.S. Food and Drug Administration (FDA) has awarded tebentafusp (IMCgp100) a "breakthrough therapy title" (BTD) for the treatment of adult patients with non-removable or metastasis staphylocolum melanoma (mUM).
-
Eur J Cancer: Levatinib significantly prolongs the survival of patients with radioactive iodine re treatable differentiated thyroid cancer, even if lung metastasis has occurred!
Time of Update: 2021-02-23
patients in each subgroup were treated with prognostic levatinib in each baseline pulmonary metastasis subgroup, with a total of 226 patients: ≥1.0 cm (n=199), ≥1.5 cm (n=150), ≥2.0 cm (n=94) and slt;2.0 cm (n=105).
, levatinib therapy can extend the survival of patients with RR-DTC with pulmonary metastasis ≥1.0 cm compared to placebo.
-
Science Sub-Journal: Beauty laser radiation is expected to enhance the anti-tumor response of immunosuppressants
Time of Update: 2021-02-23
study was published in the February 17, 2021 issue of the Journal of Science Translational Medicine under the title "Epitope spreading towards wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint responses." images from Science Translational Medicine, 2021, doi:10.1126/scitranslmed.abd8636.
-
Toripalimab is a combination of chemotherapy to treat nasopharyngeal cancer, and China's State Drug Administration has approved its application for complementary new drugs
Time of Update: 2021-02-23
Chinese pharmaceutical company Junshi Bio recently announced that China's State Drug Administration (NMPA) has accepted a new supplemental drug application for the first-line treatment of relapsed or metastatic nasopharyngeal cancer with Toripalimab combined chemotherapy.
-
A new strategy for cancer immunocell therapy has been discovered, according to a paper published in Science Translation Medicine by Shanghai Ingda Yang
Time of Update: 2021-02-16
Shanghai Jiaobo Yang and other team of researchers designed a new CAR-T cell with independent co-stimulation signal, inCAR-T cells alone continuous expression of a co-stimulation body, simulating the second signal of natural T-cell activity, the new CAR-T cell in-body culture model, lotus mouse model, and clinical patient trials showed greater amplification and tumor killing ability.
-
Ultrasound-mediated yew alcohol treats glioma through the blood-brain barrier
Time of Update: 2021-02-16
Study Methods Researchers measured the biological distribution of ultrasound and non-ultrasound-treated PTX in naked mice, and compared the distribution and efficacy of ABX and CrEL-PTX in LIPU-mediated tumors before and after LIPU, while assessing the toxicity of yew alcohol.
